Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publications 2011

Original Papers

  • Böll B, Bredenfeld H, Görgen H, Halbsguth T, Eich HT, Soekler M, Markova J, Keller U, Graeven U, Kremers S, Geissler M, Trenn G, Fuchs M, von Tresckow B, Eichenauer DA, Borchmann P, Engert A. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. 2011 Dec 8;118(24):6292-8. [Epub 2011 Sep 13].
  • Borchmann P, Haverkamp H, Fuchs M, Eich HT, Müller-Hermelink HK, Cerny T, Markova J, Ho AD, Kranz L, Greil R, Hiddemann W, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause S, Müller R-P, Diehl V, Engert A. Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin Lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG). J Clin Oncol 2011 Nov; 29(32):4234-42. [Epub 2011 Oct 11].  [Endauswertung HD12]
  • Eichenauer DA, Fuchs M, Pluetschow A, Klimm B, Halbsguth T, Böll B, von Tresckow B, Nogová L, Borchmann P, Engert A. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011 Oct 20;118(16):4363-5. [Epub 2011 Aug 9].
  • Klimm B, Franklin J, Stein H, Eichenauer D, Haverkamp H, Diehl V, Fuchs M, Borchmann P, Engert A. Lymphocyte-depleted Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group (GHSG). J Clin Oncol 2011Oct; 29(29):3914-20. [Epub 2011 Sep 12].
  • Koeck J, Abo-Madyan Y, Lohr F, Stieler F, Kriz J, Müller R-P, Wenz F, Eich HT. IMRT and Involved-Node Radiotherapy for Early Mediastinal Hodgkin Lymphoma According to the Guidelines of the German Hodgkin Study Group (GHSG). IJROBP 2011 (in press). [Epub 2011 Nov 11].
  • Markova J*, Kahraman D*, Kobe C, Skopalova M, Klaskova K, Dedeckova K, Eich HT, Dietlein M, Kozak T. The role of FDG-PET for early therapy assessment and during follow-up in patients with advanced Hodgkin Lymphoma treated with BEACOPP. Leuk Lymphoma 2012 Jan; 53(1):64-70. [Epub 2011 Aug 24]. [*Both authors contributed equally to this work.].


  • Borchmann P, Engert A, Diehl V. Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence! Nat Rev Clin Oncol. 2011 Oct 4;8(11):636-7. doi: 10.1038/nrclinonc.2011.149. 
  • Eichenauer DA, Engert A. Therapy-related myeloid neoplasms in patients treated for hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2011;3(1):e2011046. [Epub 2011 Oct 24].
  • Eichenauer DA, Engert A, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011 Sep;22 Suppl 6:vi55-8. 
  • Halbsguth TV, Böll B, Borchmann P, Diehl V. The Unique Characteristics and Management of Patients Over 60 Years of Age with Classic Hodgkin Lymphoma. Curr Hematol Malig Rep. Sep;6(3):164-171. 
  • von Tresckow B, Engert A. The Role of Autologous Transplantation in Hodgkin Lymphoma. Curr Hematol Malig Rep. 2011 Sep;6(3):172-179